Albertine Donker

Chapter 3 126 40. Bosio S, De Gobbi M, Roetto A, et al. Anemia and iron overload due to compound heterozygosity for novel ceruloplasmin mutations. Blood. 2002;100(6):2246-2248. 41. Roberti Mdo R, Borges Filho HM, Goncalves CH, Lima FL. Aceruloplasminemia: a rare disease - diagnosis and treatment of two cases. Revista brasileira de hematologia e hemoterapia. 2011;33(5):389-392. 42. Suzuki Y, Yoshida K, Aburakawa Y, et al. Effectiveness of oral iron chelator treatment with deferasirox in an aceruloplasminemia patient with a novel ceruloplasmin gene mutation. Internal medicine (Tokyo, Japan). 2013;52(13):1527-1530. 43. Finkenstedt A, Wolf E, Hofner E, et al. Hepatic but not brain iron is rapidly chelated by deferasirox in aceruloplasminemia due to a novel gene mutation. Journal of hepatology. 2010;53(6):1101-1107. 44. Kuhn J, Bewermeyer H, Miyajima H, Takahashi Y, Kuhn KF, Hoogenraad TU. Treatment of symptomatic heterozygous aceruloplasminemia with oral zinc sulphate. Brain & development. 2007;29(7):450-453. 45. SkidmoreFM,DragoV,FosterP,Schmalfuss IM, Heilman KM, Streiff RR. Aceruloplasminaemia with progressive atrophy without brain iron overload: treatment with oral chelation. Journal of neurology, neurosurgery, and psychiatry. 2008;79(4):467-470. 46. Logan JI, Harveyson KB, Wisdom GB, Hughes AE, Archbold GP. Hereditary caeruloplasmin deficiency, dementia and diabetes mellitus. QJM : monthly journal of the Association of Physicians. 1994;87(11):663-670. 47. Yazaki M, Yoshida K, Nakamura A, et al. Anovel splicing mutation in the ceruloplasmin gene responsible for hereditary ceruloplasmin deficiency with hemosiderosis. Journal of the neurological sciences. 1998;156(1):30-34. 48. Beutler E, Gelbart T, Lee P, Trevino R, Fernandez MA, Fairbanks VF. Molecular characterization of a case of atransferrinemia. Blood. 2000;96(13):4071-4074. 49. Heilmeyer L, Keller W, Vivell O, et al. [Congenital atransferrinemia in a 7-year-old girl]. Deutsche medizinische Wochenschrift (1946). 1961;86:1745-1751. 50. Hayashi A, Wada Y, Suzuki T, Shimizu A. Studies on familial hypotransferrinemia: unique clinical course and molecular pathology. American journal of human genetics. 1993;53(1):201-213. 51. Trombini P, Coliva T, Nemeth E, et al. Effects of plasma transfusion on hepcidin production in human congenital hypotransferrinemia. Haematologica. 2007;92(10):1407-1410. 52. Bartnikas TB, Andrews NC, Fleming MD. Transferrin is a major determinant of hepcidin expression in hypotransferrinemic mice. Blood. 2011;117(2):630-637. 53. Shamsian BS, Rezaei N, Arzanian MT, Alavi S, Khojasteh O, Eghbali A. Severe hypochromic microcytic anemia in a patient with congenital atransferrinemia. Pediatric hematology and oncology. 2009;26(5):356-362. 54. Hamill RL, Woods JC, Cook BA. Congenital atransferrinemia. A case report and review of the literature. American journal of clinical pathology. 1991;96(2):215-218. 55. Hromec A, Payer Jr J, Killinger Z, Rybar I, Rovenský J. [Congenital atransferrinemia]. Deutsche medizinische Wochenschrift (1946). 1994;119(18):663-666. 56. Goldwurm S, Casati C, Venturi N, et al. Biochemical and genetic defects underlying human congenital hypotransferrinemia. The hematology journal : the official journal of the European Haematology Association / EHA. 2000;1(6):390-398. 57. Canonne-Hergaux F, Zhang AS, Ponka P, Gros P. Characterization of the iron transporter DMT1 (NRAMP2/DCT1) in red blood cells of normal and anemic mk/mk mice. Blood. 2001;98(13):3823-3830. 58. Fleming MD, Trenor CC, 3rd, Su MA, et al. Microcytic anaemia mice have a mutation in Nramp2, a candidate iron transporter gene. Nature genetics. 1997;16(4):383-386. 59. Touret N, Martin-Orozco N, Paroutis P, et al. Molecular and cellular mechanisms